Company: FENC
Filing Date: 2025-11-17
Form Type: 8-K
Source: 0001104659-25-112912
Chunk: 0

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-11-17
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

On
November 13, 2025, Fennec Pharmaceuticals Inc. (the “ Company”) entered into an underwriting agreement (the “ Underwriting
Agreement”) with Piper Sandler & Co. and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named
therein (collectively, the “ Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 4,666,667
common shares, no par value (the “ Shares”), to the Underwriters (the “ Offering”). The Shares are to be sold at
a public offering price of $7.50 per share, and will be purchased by the Underwriters from the Company at a price of $6.975 per Share.
The Company also granted the Underwriters a 30-day option to purchase up to an additional 700,000 Shares at the public offering price,
less underwriting discounts and commissions. The Offering is expected to close on November 17, 2025, subject to the satisfaction of customary
closing conditions.

The
Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the
Company’s effective shelf registration statement on Form S-3 (Registration No. 333-275452), which was
previously filed with the Securities Exchange Commission on November 9, 2023 and declared effective on December 15, 2023.

A
copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The Underwriting Agreement
contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations
of the Company and the Underwriters. The representations, warranties and covenants contained in the Underwriting Agreement were made only
for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to the Underwriting Agreement.
The foregoing descriptions of the Underwriting Agreement do not purport to be complete and are qualified in their entirety by reference
to such exhibits. The provisions of the Underwriting Agreement, including any representations and warranties contained therein, are not
for the benefit of any party other than the parties to the Underwriting Agreement and are not intended for investors and the public to
obtain factual information about the current state of affairs of the parties. Rather, for information about the Company, investors and
the public should